|
|
|
|
|
|
Spring Meeting: Tempus CSO, Kevin White, to Speak
Dr. Kevin White, Chief Science Officer at Tempus, a technology company advancing precision medicine through the application of artificial intelligence in diagnosis and treatment, will speak at ALDA Spring Meeting. Dr. White’s presentation will focus on how Tempus is using AI in diagnostics applications.
At Tempus, Dr. White oversees the scientific operation. Dr. White was the founding Director of the Institute for the Institute of Genomics and Systems Biology at the University of Chicago, where he retains an appointment as the James and Karen Frank Family Professor of Human Genetics and Medicine.
Dr. White is a pioneer in combining experimental and computational techniques to understand the network of factors that control biological systems during development, disease and evolution. His team has discovered novel cancer genes in a wide range of tumor types including breast cancer, kidney cancer, and myeloid leukemias.
His academic awards for innovation include Keck Biomedical Investigator and Beckman Young Investigator awards.
Dr. White holds scientific advisory board positions at institutions that include Harvard, Yale, and Northwestern Universities, and the National Cancer Institute. Dr. White received B.S. and M.S. degrees from Yale and a Ph.D. from Stanford.
|
|
Plan to Participate in our ALDA-Endorsed Salary Survey
Special Fee of $995 for ALDA Members
ALDA members are invited to participate in the Pearl Meyer 2020 CHiPS One World Total Compensation Survey. A special section will report data covering ALDA members.
Members of ALDA are eligible to receive the special rate of $995.
The 2020 survey will cover a wide range of jobs including industry-specific positions in sales, service and R&D. Actual compensation data on all elements of the employee pay package will be reported to help your company analyze its competitive position and compensation mix from a total compensation perspective.
Participating ALDA companies will receive three reports: 1) an all-participants report, 2) a customized peer group report, and 3) an ALDA-only report, along with a full year of 24/7 access to CHiPs online with free on-demand features.
Pearl Meyer also offers a special benefit - dedicated one-to-one account support to assist your company through the job-matching and submission process, and to help you to understand how the survey results apply to your organization and its unique compensation needs.
Even if your company participates in another compensation survey, the ALDA-endorsed survey will provide valuable information allowing you to “test” the results of other surveys.
Participants’ data will be collected during the Spring with final submissions due in early May and a July 1 publication of the final report.
Pearl Meyer executives will be contacting your company directly within the next few weeks with additional details. In the meantime, if you have questions, please contact Dan Besser at Daniel.Besser@pearlmeyer.com.
ALDA endorses and sponsors its members participation in this survey with the goal of maximizing industry participation and corresponding value. We believe it is a great value at a great price.
|
|
ALDA’s Market Grew 4.0% in Q3
Life Science Sector up 4.8%, Japan Leads Regional Growth at 6.6%
ALDA’s latest Industry Market Assessment report projects the global market for ALDA members’ products exceeded US$12.0 billion in the Third calendar quarter of 2019, representing 4.0% growth year-over-year, and slightly less than Second quarter growth of 5.0%. The global market grew 5.1% in the first nine months of 2019.
The life science sector - composed of life science instrumentation, cell analysis, sample prep and reagents – once again led market growth, increasing 4.8% compared with Q3 of 2018. The sector experienced 7.4% growth for the first nine months of 2019.
All four life science market segments were up from Q3 of 2018 led by life science reagents which grew 7.0% in the quarter (8.2% in the first nine months of 2019). Life science instrumentation increased 4.2% in the quarter (6.2% in the first nine months while life science sample prep grew 2.9% and cell analysis increased 2.1% (9.1% and 3.3%, respectively, in the first three quarters).
Meanwhile, the chromatography, mass spectrometry and laboratory automation sector grew at a 3.7% rate for Q3 compared with the prior year, and 3.8% growth in the first nine months of 2019. The sector was led by mass spectrometry, which grew at a 5.5% rate and laboratory automation which rose 4.3% (4.8% and 4.9%, respectively, for the first three quarters.) Gas chromatography grew 2.8% (3.0% for the first nine months), while liquid chromatography rose 2.5% for the quarter (2.9% for the first three quarters.)
The spectroscopy and materials analysis sector grew 3.4% for the quarter, and 4.1% for the first nine months of 2019.
Regional market growth in the quarter was led by the Japan which increased 6.6% compared with Q3 of 2018, followed by Asia Pacific which grew at a 5.5% rate for the quarter, and North America at 4.2%. Europe, accounting for 27% of the global market, rose 2.2%, as did the Rest of World market comprised of countries not reported elsewhere.
The Industry Market Assessment report, prepared quarterly by Strategic Directions International (“SDi”) for members of ALDA, is based on public reports and SDi’s proprietary research. The ALDA market, composed of the 15 technology markets most important to ALDA’s membership, is estimated to be 75-80% of total global industry revenues.
|
|
|
|
|
|
|
|
